Literature DB >> 16179665

Dose effects of modafinil in sustaining wakefulness in narcolepsy patients with residual evening sleepiness.

Jonathan R L Schwartz1, Neil T Feldman, Richard K Bogan.   

Abstract

Excessive sleepiness associated with narcolepsy lasts throughout the waking day. The authors conducted two randomized, double-blind studies to compare the efficacy of modafinil once-daily versus split doses in maintaining wakefulness throughout the day. Fifty-six patients received modafinil. The split-dose regimens were significantly more effective than the 200-mg once-daily regimen for sustaining wakefulness in the late afternoon/evening. All modafinil dosing regimens were well tolerated. In patients who experience excessive sleepiness in the late afternoon/evening, despite satisfactory treatment earlier in the day, a split dose of modafinil may promote wakefulness throughout the waking day.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16179665     DOI: 10.1176/jnp.17.3.405

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  16 in total

Review 1.  Central Disorders of Hypersomnolence: Focus on the Narcolepsies and Idiopathic Hypersomnia.

Authors:  Zeeshan Khan; Lynn Marie Trotti
Journal:  Chest       Date:  2015-07       Impact factor: 9.410

2.  Comparison of steady-state plasma concentrations of armodafinil and modafinil late in the day following morning administration: post hoc analysis of two randomized, double-blind, placebo-controlled, multiple-dose studies in healthy male subjects.

Authors:  Mona Darwish; Mary Kirby; Edward T Hellriegel
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

3.  Armodafinil and modafinil have substantially different pharmacokinetic profiles despite having the same terminal half-lives: analysis of data from three randomized, single-dose, pharmacokinetic studies.

Authors:  Mona Darwish; Mary Kirby; Edward T Hellriegel; Philmore Robertson
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

4.  Effectiveness and side-effect profile of stimulant therapy as monotherapy and in combination in the central hypersomnias in clinical practice.

Authors:  Chiraag Thakrar; Kishankumar Patel; Grainne D'ancona; Brian D Kent; Alexander Nesbitt; Hugh Selsick; Joerg Steier; Ivana Rosenzweig; Adrian J Williams; Guy D Leschziner; Panagis Drakatos
Journal:  J Sleep Res       Date:  2017-10-19       Impact factor: 3.981

5.  Modafinil in the treatment of debilitating fatigue in primary biliary cirrhosis: a clinical experience.

Authors:  S Ian Gan; Mariana de Jongh; Marshall M Kaplan
Journal:  Dig Dis Sci       Date:  2008-12-12       Impact factor: 3.199

6.  Pharmacokinetic profile of armodafinil in healthy subjects: pooled analysis of data from three randomized studies.

Authors:  Mona Darwish; Mary Kirby; Edward T Hellriegel; Ronghua Yang; Philmore Robertson
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

Review 7.  Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin.

Authors:  Timothy I Morgenthaler; Vishesh K Kapur; Terry Brown; Todd J Swick; Cathy Alessi; R Nisha Aurora; Brian Boehlecke; Andrew L Chesson; Leah Friedman; Rama Maganti; Judith Owens; Jeffrey Pancer; Rochelle Zak
Journal:  Sleep       Date:  2007-12       Impact factor: 5.849

Review 8.  Treatment of narcolepsy and other hypersomnias of central origin.

Authors:  Merrill S Wise; Donna L Arand; R Robert Auger; Stephen N Brooks; Nathaniel F Watson
Journal:  Sleep       Date:  2007-12       Impact factor: 5.849

Review 9.  Idiopathic Hypersomnia and Other Hypersomnia Syndromes.

Authors:  Lynn Marie Trotti; Isabelle Arnulf
Journal:  Neurotherapeutics       Date:  2021-01       Impact factor: 7.620

10.  Modafinil in the treatment of excessive sleepiness.

Authors:  Jonathan R L Schwartz
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.